aGVHD Incidence Following HSCT May be Reduced Following Treatment With Itolizumab
Patients receiving hematopoietic stem cell transplantation appeared to have improved outcomes and a decreased incidence of acute graft-versus-host disease after being treated with itolizumab.
Treatment with itolizumab not only appeared to reduce host T cell response to donor grafts, but also…
Source: www.cancernetwork.com – Read more